21 May 2013

Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).

Read more

15 May 2013

Starpharma will today present to institutional fund managers at the Goldman Sachs Emerging Companies conference in Sydney.

 The invitation-only event involves 35 companies across all sectors.  Starpharma is one of three healthcare companies invited to attend - the other two are Blackmores and Sigma Pharmaceuticals.

Read more

13 May 2013

Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) today announced that the Company’s clinical-stage dendrimer SPL7013 has shown potent antiviral effect against adenovirus, the agent responsible for the majority of viral conjunctivitis cases.

Read more

24 April 2013

Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 March 2013.

Read more

4 April 2013

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Thursday 4^th April 2013. Ticky discussed the positive results of Starpharma’s Phase 2 prevention of recurrence BV trials.

 

 Watch the Interview (external link)

4 April 2013

AAP business reporter Trevor Chappell investigates Starpharma’s positive results for its Phase II trial of VivaGel to prevent recurring bacterial vaginosis (R-BV). The results demonstrated a reduced overall risk of R-BV.

"The commercial opportunity for recurrent BV is very attractive, with an estimated market of more than $1 billion," said Starpharma CEO Dr Jackie Fairley.

 

 Go to the article (external link)

14 March 2013

Herald Sun’s In The Black columnist, John Beveridge reported on Starpharma and its collaboration with Nufarm and Israel’s Makhreshim Agan, trading in Australia as Farmoz. These collaborations are a vote of confidence to the versatility of Starpharma’s dendrimer technology. "Dendrimers, nanoparticles that can greatly improve water solubility, are ideally suited to improving farming chemicals. In the case of weedkillers such as glyphosate, the addition of the right sort of dendrimer at the right levels can make the weedkiller much faster and more effective to use and able to be applied close to rain. For other agricultural chemicals the advantage is even greater, allowing the removal of dangerous solvents used to make theactive ingredient soluble and allowing the production of concentrates that are much easier to transport and can be mixed with water on site."

4 March 2013

Herald Sun reporters Brigid O’Connell, Lucie van den Berg and Grant McArthur featured Starpharma in a special report in The Herald Sun and The Australian online, examining cutting edge medical research being done in Melbourne.

"The home of corporate giants CSL, Mesoblast, Acrux, Biota and Starpharma, Melbourne also dominates in taking the laboratory to the marketplace: more than 85 products were on the market last year and dozens more were in trials in hopes of delivering the next generation of medical advances."

19 December 2012

In this issue:

›  Phase 3 clinical trial results for treatment of bacterial vaginosis

› Rapid resolution of symptoms; strong patient acceptability for VivaGel^®

› Taxotere’s anti-cancer effect boosted with Starpharma’s dendrimer technology

› Turning over a new leaf in the world of agrochemicals

› Starpharma wins Janssen Company of the Year Award

Download: Shareholder Update: December 2012 ( pdf file, 1MB)

Read more

8 August 2012

In this issue:

›   VivaGel^® BV trials on track for completion in 2012
›   NDA ready – activities in place to support the BV approval submission
›   Leading the way for Australian innovations
›   Starpharma’s drug delivery program progresses into exciting new areas
›   Crop protection agreement signed with Nufarm
›   Market recognition of Starpharma

Download: Shareholder Update: August 2012 ( pdf file, 1MB)

Read more